Impact of the 1425G/A polymorphism of PRKCH on the recurrence of ischemic stroke: Fukuoka stroke registry

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Epidemiologic studies have elucidated that the 1425G/A single-nucleotide polymorphism (rs2230500 single-nucleotide polymorphism) in exon 9 of the protein kinase C eta (PRKCH) gene is an independent risk factor for ischemic stroke: stroke incidence is significantly higher in the subjects with AA than those with AG or GG genotype. However, its impact on stroke recurrence remains unknown. The aim of the present study was to clarify whether the polymorphism is also a risk factor for recurrent stroke in patients with acute ischemic stroke. Methods We enrolled 2418 consecutive patients with acute and first-ever ischemic stroke and investigated the 1425G/A polymorphism of PRKCH. Patients were followed up for a median of 733 days. The association between the polymorphism and stroke recurrence was investigated using the Cox proportional hazard model. Results In the enrolled patients, the GG genotype was the most prevalent (63%), followed by AG (32%) and AA genotypes (5%). Recurrent stroke occurred in 302 patients during the follow-up period. Kaplan-Meier analyses revealed no difference in the rate of recurrent stroke after first-ever stroke among the 3 genotypes. The incidence of recurrent stroke was not significantly different in patients with AA (hazard ratio [HR] 1.02, 95% confidence interval.59-1.64, P =.94) or AG (HR.89, 95% confidence interval.69-1.14, P =.36) genotypes compared with those with the GG genotype after adjusting for multiple confounders. Conclusions The 1425G/A polymorphism in PRKCH is not a significant predictor of stroke recurrence in patients with acute ischemic stroke during a 2-year follow-up period.

Original languageEnglish
Pages (from-to)1356-1361
Number of pages6
JournalJournal of Stroke and Cerebrovascular Diseases
Volume23
Issue number6
DOIs
Publication statusPublished - Jul 2014

Fingerprint

Registries
Stroke
Recurrence
Genotype
Single Nucleotide Polymorphism
Incidence
Kaplan-Meier Estimate
Proportional Hazards Models
Epidemiologic Studies
Exons

All Science Journal Classification (ASJC) codes

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

@article{16dc32d542d0414785e22a9baba6e0e2,
title = "Impact of the 1425G/A polymorphism of PRKCH on the recurrence of ischemic stroke: Fukuoka stroke registry",
abstract = "Background Epidemiologic studies have elucidated that the 1425G/A single-nucleotide polymorphism (rs2230500 single-nucleotide polymorphism) in exon 9 of the protein kinase C eta (PRKCH) gene is an independent risk factor for ischemic stroke: stroke incidence is significantly higher in the subjects with AA than those with AG or GG genotype. However, its impact on stroke recurrence remains unknown. The aim of the present study was to clarify whether the polymorphism is also a risk factor for recurrent stroke in patients with acute ischemic stroke. Methods We enrolled 2418 consecutive patients with acute and first-ever ischemic stroke and investigated the 1425G/A polymorphism of PRKCH. Patients were followed up for a median of 733 days. The association between the polymorphism and stroke recurrence was investigated using the Cox proportional hazard model. Results In the enrolled patients, the GG genotype was the most prevalent (63{\%}), followed by AG (32{\%}) and AA genotypes (5{\%}). Recurrent stroke occurred in 302 patients during the follow-up period. Kaplan-Meier analyses revealed no difference in the rate of recurrent stroke after first-ever stroke among the 3 genotypes. The incidence of recurrent stroke was not significantly different in patients with AA (hazard ratio [HR] 1.02, 95{\%} confidence interval.59-1.64, P =.94) or AG (HR.89, 95{\%} confidence interval.69-1.14, P =.36) genotypes compared with those with the GG genotype after adjusting for multiple confounders. Conclusions The 1425G/A polymorphism in PRKCH is not a significant predictor of stroke recurrence in patients with acute ischemic stroke during a 2-year follow-up period.",
author = "Ryu Matsuo and Tetsuro Ago and Jun Hata and Junya Kuroda and Yoshinobu Wakisaka and Hiroshi Sugimori and Takanari Kitazono and Masahiro Kamouchi",
year = "2014",
month = "7",
doi = "10.1016/j.jstrokecerebrovasdis.2013.11.011",
language = "English",
volume = "23",
pages = "1356--1361",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Impact of the 1425G/A polymorphism of PRKCH on the recurrence of ischemic stroke

T2 - Fukuoka stroke registry

AU - Matsuo, Ryu

AU - Ago, Tetsuro

AU - Hata, Jun

AU - Kuroda, Junya

AU - Wakisaka, Yoshinobu

AU - Sugimori, Hiroshi

AU - Kitazono, Takanari

AU - Kamouchi, Masahiro

PY - 2014/7

Y1 - 2014/7

N2 - Background Epidemiologic studies have elucidated that the 1425G/A single-nucleotide polymorphism (rs2230500 single-nucleotide polymorphism) in exon 9 of the protein kinase C eta (PRKCH) gene is an independent risk factor for ischemic stroke: stroke incidence is significantly higher in the subjects with AA than those with AG or GG genotype. However, its impact on stroke recurrence remains unknown. The aim of the present study was to clarify whether the polymorphism is also a risk factor for recurrent stroke in patients with acute ischemic stroke. Methods We enrolled 2418 consecutive patients with acute and first-ever ischemic stroke and investigated the 1425G/A polymorphism of PRKCH. Patients were followed up for a median of 733 days. The association between the polymorphism and stroke recurrence was investigated using the Cox proportional hazard model. Results In the enrolled patients, the GG genotype was the most prevalent (63%), followed by AG (32%) and AA genotypes (5%). Recurrent stroke occurred in 302 patients during the follow-up period. Kaplan-Meier analyses revealed no difference in the rate of recurrent stroke after first-ever stroke among the 3 genotypes. The incidence of recurrent stroke was not significantly different in patients with AA (hazard ratio [HR] 1.02, 95% confidence interval.59-1.64, P =.94) or AG (HR.89, 95% confidence interval.69-1.14, P =.36) genotypes compared with those with the GG genotype after adjusting for multiple confounders. Conclusions The 1425G/A polymorphism in PRKCH is not a significant predictor of stroke recurrence in patients with acute ischemic stroke during a 2-year follow-up period.

AB - Background Epidemiologic studies have elucidated that the 1425G/A single-nucleotide polymorphism (rs2230500 single-nucleotide polymorphism) in exon 9 of the protein kinase C eta (PRKCH) gene is an independent risk factor for ischemic stroke: stroke incidence is significantly higher in the subjects with AA than those with AG or GG genotype. However, its impact on stroke recurrence remains unknown. The aim of the present study was to clarify whether the polymorphism is also a risk factor for recurrent stroke in patients with acute ischemic stroke. Methods We enrolled 2418 consecutive patients with acute and first-ever ischemic stroke and investigated the 1425G/A polymorphism of PRKCH. Patients were followed up for a median of 733 days. The association between the polymorphism and stroke recurrence was investigated using the Cox proportional hazard model. Results In the enrolled patients, the GG genotype was the most prevalent (63%), followed by AG (32%) and AA genotypes (5%). Recurrent stroke occurred in 302 patients during the follow-up period. Kaplan-Meier analyses revealed no difference in the rate of recurrent stroke after first-ever stroke among the 3 genotypes. The incidence of recurrent stroke was not significantly different in patients with AA (hazard ratio [HR] 1.02, 95% confidence interval.59-1.64, P =.94) or AG (HR.89, 95% confidence interval.69-1.14, P =.36) genotypes compared with those with the GG genotype after adjusting for multiple confounders. Conclusions The 1425G/A polymorphism in PRKCH is not a significant predictor of stroke recurrence in patients with acute ischemic stroke during a 2-year follow-up period.

UR - http://www.scopus.com/inward/record.url?scp=84902449157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902449157&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2013.11.011

DO - 10.1016/j.jstrokecerebrovasdis.2013.11.011

M3 - Article

C2 - 24534126

AN - SCOPUS:84902449157

VL - 23

SP - 1356

EP - 1361

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 6

ER -